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Purpose/Objective: To evaluate acute and late injury of kidney in 
radiotherapy of patients with gastric cancer. 
Materials and Methods: Twenty patients with gastric cancer that 
were treated with post operative chemoradiation were prospectively 
evaluated. Chemotherapy was done with 5FU and LV (400 mg/m2 5FU, 
30 mg/m2 LV) in 4 first and 3 last days of radiotherapy.Total radiation 
dose of 45 Gy was delivered in 25 fractions (5 days a week) with 1.8 
Gy dose per fraction by 2 opposed fields. In this study, decrease of 
glomerular filtration rate (GFR) value was used for definition of 
toxicity. The GFR value be measured using 99mTc-diethylene 
triaminepentaacetic acid (DTPA) scan that was done for all of the 
patients before, during (in 15thsession of radiotherapy) and 3 to 9 
months after radiotherapy. The imaging was done using dual head 
gamma camera. 
Results: There was a significant reduction in the GFR values of 
irradiated kidneys. 
Conclusions: 99mTc-DTPA scan can be a suitable modality for 
determining of renal toxicity after radiotherapy of gastric cancers. 
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Purpose/Objective: We report initial experience with CyberKnife (CK) 
in patients hepatocellular carcinoma (HCC), liver metastasis (LM) and 
Klastkin tumour (KT).  
Materials and Methods: Seventeen consecutive patients (mean age 
57.5 years, range 35-81 yrs; 82% male) treated with fiducial based 
robotic radiosurgery. Nine patients had HCC (n=9) and four each had 
LM (n=4) and KT (n=4). 11/17 patient (70%) were with Child Pugh 
A/B,8/9 with HCC had infective hepatitis (4 each with hepatitis B & 
C), 5/17(29%) had diffuse cirrhosis, 70%(12/17) had single lesion in 
liver and target volume 90 cc in 6 (35%)patients respectively. 13/17 
(75%) patients had prior treatment [chemotherapy8/13 (61%), TACE 
5/13 (39%)] and treated with SBRT on progression. All patients were 
treated with 3 fractions (21-45Gy/3#; mean dose 33Gy, prescription 
isodose84%, target coverage 94%); fiducial tracking based CK. Mean CI, 
nCI, HI was1.13, 1.28 and 1.19 respectively. Mean liver dose was 4.7 
Gy, 800cc liver dose 8.2 Gy; 2% small intestine dose 10.6 Gy. Mean 
nodes, beamlets, monitor units and treatment time 69, 174, 46919 
and 60.4 min respectively. 
Results: At mean follow up of 11.3 months (range 1.9-26.5), 12/17 
(70%) patients expiredand 5/17 (30%) alive (3 patient with controlled 
primary, one each with local progression and metastasis). Median 
overall survival (OS) in HCC patients was11.9 months (2.1-26.5 
months), MT 8.3 months (1.9-13.3 months) and KT was 12.8 months 
(7.4-25 months) respectively. 5/17 (30%) patients had grade I-II GI 
toxicities, no grade III-IV toxicities were observed and only one 
patient (12%) had anicteric ascites with high serum alkaline 
phosphatase two months after CK and recovered with supportive care. 
Median OS (month) were significantly influenced by factors such as 
performance status (KPS 70-80 vs 90-100: 8.3 vs 15.4; p=0.034), Child 
Pugh (CPA/B vs C: 13.3 vs 4.9; p=0.039), cirrhosis (only fatty liver vs 
diffusecirrhosis: 13.3 vs 9.4; p=0.005), prior treatment (no Rx vs prior 
Rx: 16.6 vs8.3; p=0.006), dose (39Gy: 9.5 vs 15.4; p=0.02) and target 
volume (90 cc: 15.7 vs 7.7; p=0.011) respectively. There was no 
fiducial related toxicity or migration. 
Conclusions: CyberKnife is safe and effective local treatment 
modality in selected patients with liver malignancies with minimal 
adverse events. Factors such as performace status, Child Pugh 
classification, cirrhosis status, prior treatment, RT dose andtarget 
volume significantly influence survival function. 
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Purpose/Objective: To assess the outcome of non metastatic 
esophagus cancer according to therapeutic strategy: evolution of 
esophagus cancer after curative treatment, results and toxicities of 
combined treatments and factors which can influence disease local 
control, disease-free and overall survival. 
Materials and Methods: 120 patients with exclusive 
radiochemotherapy (RC) and possibly surgery between 2004 and 2010 
treated esophagus cancer were retrospectively studied. The first site 
of relapse was classified as follows: local (tumor), locoregional (tumor 
and/or nodal: coeliaq, mediastinal, sus-clavicular) or metastatic. 
Patients had TEP-FDG before performing treatment to help for GTV 
delineation. 
Results: With a 15,7 months (1,4-62) median follow-up, there was 89 
deaths and 77 recurrence.Three types of treatments were performed: 
50 Gray (Gy) exclusive radiochemoterapy (RC) (47 patients) or 50 to 
65 Gy exclusive RC (44 patients) or RC followed by surgery (27 
patients). RC was performed after surgery for 2 patients. Local first 
relapse was as much frequent as distance relapse (50 patients). With 5 
cm marging up and down to the tumor, there was only one beam 
border nodal relapse. Two-year survival was 39,5% (95% confidence 
interval [IC]: 30,5-40,8) and relapse-free survival was 26,5% (IC: 18,6-
35). Multivariate analysis has revealed that treatment type and 
disease stade had a significant impact on survival, relapse-free 
survival and locoregional control. Compared to exclusive RC, surgery 
improved locoregional control (40,2 versus 8.7 months, p=0.0004) but 
in a younger population. Despite post-operative mortality, the gain 
was maintained for distance relapse-free survival (40.2 versus 10 
months, p=0.0147)and overall survival (29.3 versus 14.2 months, 
p=0.0088). Compared to 50 Gy RC, local control was improved if high 
dose RC was performed (13.8 versus 7.5 months, p=0.05) but not 
overall survival (14.0 versus 15.4 months, p=0.24). Incidence of late 
grade 3 treatment toxicity was not different between three arms 
(p=0.007). 
Conclusions: Despite multidisciplinary care, esophagus cancer 
pronostic is still poor. More than one third relapse was local. 
Locoregional control was better with high dose RC. Surgery, 
performed in selected patients only, improved locoregional control, 
relapse-free disease and overall survival. With only one beam border 
recurrence, nodal elective irradiation seemed to be not usefull. These 
results have to be confirmed by a soon opening phase III dose 
escalation EqualEstro approved study: Concorde. 
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Purpose/Objective: Chemotherapy (CT) is confirmed to prolong 
survival in metastatic and inoperable locally advanced gastric 
carcinoma as compared to the best supportive care. Earlier in 
retrospective study we’d shown radiotherapy and chemoradiation 
(CRT) were superior to chemotherapy in terms of overall survival. In 
the present study we analyze preliminary results of one-center 
randomized trial to compare chemoradiation with chemotherapy for 
inoperable, locally advanced gastric carcinoma (ILAGC). 
Materials and Methods: Beginning from January, 2010 patients with 
ILAGC were prospectively randomized to CT or CRT. Inclusion criteria 
were histological confirmation of GC, absence of evident metastatic 
disease, general condition 0-2 by ECOG scale, dysphagia 0-1, and 
normal laboratory tests. In CRT group the treatment was started from 
2D irradiation to 60 Gy, 30 fractions: initially, from two parallel-
opposed fields encompassing both primary and regional lymphatics 
with shielding of kidneys, then last ten fractions were delivered to 
primary only, isocentrically, evading spinal cord. Chemotherapy being 
the same in both groups consisted of Cisplatinum 100 mg per m2 D1 
and 24 h infusion of 5-Fluorouracil 1000 mg per m2 D1-5 every four 
weeks, up to 6 courses. Primary endpoint was overall survival, 
calculated as a time gap between the start of treatment and death 
from any reason. The distribution by initial characteristics and survival 
were compared using chi-square and log-rank methods respectively. 
Results: At the moment of analysis 59 patients with ILAGC were 
randomized, 29 for CRT, 30 to CT. Twenty four (59%) pts died, 9 pts 
are continuing treatment, median follow-up is 14 months. Forty six 
(78%), 44 (75%) and 49 (83%) patients had Stage 3 (TNM 7), T4 and 
exploratory surgery, respectively. The distribution on basic initial 
parameters was similar. The total dose of at least 50 Gy delivered to 
